Suggestions
Parag Mehta
CEO at Aveta Biomics
Parag Mehta is the CEO of Aveta Biomics, a clinical-stage biopharmaceutical company based in the Boston area.12 He has been serving in this role since November 2013.1 Aveta Biomics focuses on developing novel Network Modulating Therapeutics to overcome drug resistance and off-target adverse effects, aiming to provide durable clinical responses.1
Under Parag's leadership, Aveta Biomics is:
- Conducting an ongoing clinical trial for Head and Neck cancer1
- Developing a new class of drugs to combat antibiotic resistance1
- Pioneering nature-inspired drugs using insights from evolutionary biology2
Parag G. Mehta holds a Ph.D. and serves not only as the CEO but also as a Board Director at Aveta Biomics.2 The company's platform is designed to create the next generation of first-in-class immuno-oncology drugs.2
In February 2022, Aveta Biomics, under Parag's leadership, secured an exclusive license from CSIR-Central Drug Research Institute (CDRI) for Caviunin-based drug compositions, expanding their portfolio into bone health drugs.3
Highlights
At Aveta Biomics, our commitment to finding cure for head and neck cancer is deeply personal. We've lost loved ones to this devastating disease, which drives our passion to develop new treatments this cancer. Very pleased to share that FDA has now granted a rare Fast Track Designation to our drug APG-157 for neoadjuvant treatment of head and neck cancer.
Aveta Biomics Commences Clinical Trial for High-Grade Glioma (Brain Cancer)
We are pleased to announce that Aveta Biomics has initiated Phase 1B/2A clinical trial for APG-157 for recurrent high-grade glioma at Mayo Clinic, Rochester, MN, and at Buffett Cancer Center at the University of Nebraska Medical Center in Omaha, NE. High-grade glioma, a devastating form of brain cancer, poses significant challenges for patients and healthcare providers. High-grade glioma includes Glioblastoma – Grade 4 glioma - which many of you may have heard about. The prognosis for those suffering from this aggressive disease is often limited, highlighting the critical need for innovative treatment options.
Our novel drug, APG-157, is now being evaluated in combination with the standard of care, Bevacizumab, in a clinical trial setting. This combination, based on a unique scientific rationale, offers the patients enrolled in this trial a new option. We are excited about the potential impact of our trial to help Glioma patients. For more information check out NCT06011109.
https://lnkd.in/e6GaD5yz
